This company listing is no longer active
Scandion Oncology Past Earnings Performance
Past criteria checks 0/6
Key information
-56.8%
Earnings growth rate
-26.3%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | n/a |
| Return on equity | -60.8% |
| Net Margin | n/a |
| Next Earnings Update | 25 Aug 2022 |
Recent past performance updates
No updates
Recent updates
No updates
Revenue & Expenses Breakdown
How Scandion Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 22 | 0 | -56 | 10 | 53 |
| 31 Dec 21 | 0 | -52 | 8 | 48 |
| 30 Sep 21 | 0 | -43 | 22 | 30 |
| 30 Jun 21 | 0 | -31 | 11 | 30 |
| 31 Mar 21 | 0 | -22 | 1 | 30 |
| 31 Dec 20 | 0 | -17 | 3 | 22 |
| 30 Sep 20 | 0 | -11 | 27 | 0 |
| 30 Jun 20 | 0 | -14 | 23 | 0 |
| 31 Mar 20 | 0 | -14 | 19 | 0 |
| 31 Dec 19 | 0 | -12 | 16 | 0 |
| 30 Sep 19 | 0 | -17 | 5 | 0 |
| 30 Jun 19 | 0 | -12 | 4 | 0 |
| 31 Mar 19 | 0 | -10 | 3 | 0 |
| 31 Dec 18 | 0 | -8 | 3 | 0 |
| 30 Sep 18 | 0 | -4 | 1 | 0 |
Quality Earnings: SCOL BTA is currently unprofitable.
Growing Profit Margin: SCOL BTA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SCOL BTA is unprofitable, and losses have increased over the past 5 years at a rate of 56.8% per year.
Accelerating Growth: Unable to compare SCOL BTA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SCOL BTA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-12.6%).
Return on Equity
High ROE: SCOL BTA has a negative Return on Equity (-60.84%), as it is currently unprofitable.